Lumida
/GH
⌘K
Guardant Health Inc

Guardant Health Inc

GH
$157.38USD-1.04%-1.65 today

MARKET CAP

21.1B

P/E (TTM)

FWD P/E

DAY RANGE

$156 – $161

52W RANGE

$53
$177

AI Summary

Stalk
StalkMedium

GH is in a robust Stage 2 advance with a parabolic acceleration above rising EMAs, anchoring bullish medium- and long-term biases. However, extreme overbought conditions and an exhaustion candle near the peak suggest near-term timing is unfavorable. Execution should be deferred until a pullback into the rising EMA 9/21 support zone or prior consolidation range confirms renewed buying interest.

  • Q2 2026 revenue reached $335M, up 44% YoY driven by Guardant360 and Shield tests.
  • Oncology test volumes climbed 63% YoY to ~104K tests, reflecting strong market adoption.
  • Patent infringement verdict carries $245.2M damages, straining cash flows and management focus.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$373.7M$449.5M$563.9M$739.0M$982.0M
YoY %+30.3%+20.3%+25.5%+31.0%+32.9%
P / Sales27.1x6.1x5.3x5.1x13.0x
EV / Sales30.0x9.3x6.1x6.6x14.8x
Gross Profit, Adj.$250.7M$293.2M$336.9M$449.2M$633.0M
YoY %+29.1%+16.9%+14.9%+33.3%+40.9%
Margin %67.1%65.2%59.7%60.8%64.5%
EV / Gross Profit44.7x14.2x10.3x10.8x23.0x
EBITDA, Adj.$-388.7M$-508.4M$-521.8M$-401.2M$-397.5M
YoY %-62.7%-30.8%-2.6%+23.1%+0.9%
Margin %-104.0%-113.1%-92.5%-54.3%-40.5%
EV / EBITDA-28.8x-8.2x-6.6x-12.1x-36.6x
EBIT$-411.0M$-544.4M$-564.7M$-443.6M$-437.2M
YoY %-61.2%-32.5%-3.7%+21.4%+1.4%
Margin %-110.0%-121.1%-100.1%-60.0%-44.5%
EV / EBIT-27.3x-7.7x-6.1x-10.9x-33.3x
Net Income$-405.7M$-654.6M$-479.4M$-436.4M$-416.3M
YoY %-59.8%-61.4%+26.8%+9.0%+4.6%
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (GAAP)-$4.00-$6.41-$4.28-$3.56-$3.32
YoY %-53.8%-60.3%+33.2%+16.8%+6.7%